SE0102627D0 - Methylation resistant vectors - Google Patents

Methylation resistant vectors

Info

Publication number
SE0102627D0
SE0102627D0 SE0102627A SE0102627A SE0102627D0 SE 0102627 D0 SE0102627 D0 SE 0102627D0 SE 0102627 A SE0102627 A SE 0102627A SE 0102627 A SE0102627 A SE 0102627A SE 0102627 D0 SE0102627 D0 SE 0102627D0
Authority
SE
Sweden
Prior art keywords
host cell
vectors
methylation
receiver host
receiver
Prior art date
Application number
SE0102627A
Other languages
Swedish (sv)
Other versions
SE518759C2 (en
SE0102627L (en
Inventor
Bengt Widegren
Bertil Persson
Leif G Salford
Original Assignee
Bengt Widegren
Bertil Persson
Leif G Salford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bengt Widegren, Bertil Persson, Leif G Salford filed Critical Bengt Widegren
Priority to SE0102627A priority Critical patent/SE0102627L/en
Publication of SE0102627D0 publication Critical patent/SE0102627D0/en
Priority to PCT/SE2002/001121 priority patent/WO2003012112A1/en
Priority to CA002453372A priority patent/CA2453372A1/en
Priority to MXPA04000651A priority patent/MXPA04000651A/en
Priority to JP2003517286A priority patent/JP2004536616A/en
Priority to EP02741568A priority patent/EP1419257A1/en
Publication of SE518759C2 publication Critical patent/SE518759C2/en
Publication of SE0102627L publication Critical patent/SE0102627L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to vectors produced in a donor host cell, which upon transfer into a receiver host cell maintain the desired expression of the nucleotide sequences which are located within the vector. The maintenance of the desired expression is achieved due to that the vector at least partly remains unmethylated within the receiver host cell. The donor host cell being different as compared to the receiver host cell and the receiver host cell being capable of methylating DNA. To prevent methylation, cytosines in a CpG motif in the nucleotide sequence to be transferred are replaced with cytosine analogues resistant to methylation. The invention also relates to methods for the production of such vectors and the use of the vectors in industry as well as in medicine.
SE0102627A 2001-07-27 2001-07-27 Vectors resistant to methylation SE0102627L (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE0102627A SE0102627L (en) 2001-07-27 2001-07-27 Vectors resistant to methylation
PCT/SE2002/001121 WO2003012112A1 (en) 2001-07-27 2002-07-08 Methylation resistant vectors
CA002453372A CA2453372A1 (en) 2001-07-27 2002-07-08 Methylation resistant vectors
MXPA04000651A MXPA04000651A (en) 2001-07-27 2002-07-08 Methylation resistant vectors.
JP2003517286A JP2004536616A (en) 2001-07-27 2002-07-08 Methylation resistant vector
EP02741568A EP1419257A1 (en) 2001-07-27 2002-07-08 Methylation resistant vectors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102627A SE0102627L (en) 2001-07-27 2001-07-27 Vectors resistant to methylation

Publications (3)

Publication Number Publication Date
SE0102627D0 true SE0102627D0 (en) 2001-07-27
SE518759C2 SE518759C2 (en) 2002-11-19
SE0102627L SE0102627L (en) 2002-11-19

Family

ID=20284952

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102627A SE0102627L (en) 2001-07-27 2001-07-27 Vectors resistant to methylation

Country Status (6)

Country Link
EP (1) EP1419257A1 (en)
JP (1) JP2004536616A (en)
CA (1) CA2453372A1 (en)
MX (1) MXPA04000651A (en)
SE (1) SE0102627L (en)
WO (1) WO2003012112A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2845585C (en) 2011-08-30 2020-02-18 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
FR2981946B1 (en) * 2011-10-28 2015-02-20 Lfb Biotechnologies TRANSCRIPTION UNITS AND THEIR USE IN EXPRESSION VECTORS (YB2 / 0)
MX2018000016A (en) 2015-07-02 2019-01-31 Otsuka Pharma Co Ltd Lyophilized pharmaceutical compositions.
AU2018310857A1 (en) 2017-08-03 2020-02-13 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552277A (en) * 1994-07-19 1996-09-03 The Johns Hopkins University School Of Medicine Genetic diagnosis of prostate cancer
WO1996012008A1 (en) * 1994-10-13 1996-04-25 Merck & Co., Inc. Synthesis of methylase-resistant genes
US6783933B1 (en) * 1999-09-15 2004-08-31 The Johns Hopkins University School Of Medicine CACNA1G polynucleotide, polypeptide and methods of use therefor
AU8021500A (en) * 1999-10-13 2001-04-23 Johns Hopkins University School Of Medicine, The Methods of diagnosing and treating hepatic cell proliferative disorders
WO2001029235A2 (en) * 1999-10-18 2001-04-26 Emory University Tms1 compositions and methods of use

Also Published As

Publication number Publication date
SE518759C2 (en) 2002-11-19
MXPA04000651A (en) 2004-10-27
WO2003012112A1 (en) 2003-02-13
EP1419257A1 (en) 2004-05-19
SE0102627L (en) 2002-11-19
CA2453372A1 (en) 2003-02-13
JP2004536616A (en) 2004-12-09

Similar Documents

Publication Publication Date Title
IN2012DN00403A (en)
MX2009009530A (en) Double-stranded locked nucleic acid compositions.
NZ563845A (en) RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic
NZ591416A (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP1750771A4 (en) Pancreatic islet microrna and methods for inhibiting same
NZ585327A (en) Lna antagonists targeting the androgen receptor
WO2003086280A3 (en) Immunostimulatory g,u-containing oligoribonucleotides
MY145619A (en) Oligonucleotide analogues incorporating 5-aza-cytosine therein
MX2009012482A (en) Class a oligonucleotides with immunostimulatory potency.
IL159758A (en) Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
MXPA01010392A (en) Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences.
EA201171131A1 (en) IMPROVED DETERMINATION OF GENE EXPRESSION
HK1154623A1 (en) Isolated luciferases and the use thereof
SE0102627D0 (en) Methylation resistant vectors
PE20021008A1 (en) COMPOSITIONS FOR ANTIBACTERIAL VACCINE
EP1209228A3 (en) Environmental stress responsive promoter
IL163745A0 (en) Use of adenoviruses mutated in the va genes for cancer treatment
ES2286212T3 (en) SPECIFICALLY DELETED SEQUENCES OF THE MYCOBACTERIUM TUBERCULOSIS GENOME, AND ITS USE IN THE DIAGNOSIS AND AS VACCINES.
HK1090663A1 (en) Chicken rna polymerase i promoter and the use thereof
NO20030052L (en) Genes and their gene products relevant to microsatellite unstable (MSI +) tumors
MXPA05008329A (en) Use of a novel polymorphism in the hsgk1 gene in the diagnosis of hypertonia and use of the sgk gene family in the diagnosis and therapy of the long qt syndrome.
ES2530716T3 (en) Pestivirus species
DE60032328D1 (en) PROCESS FOR THE PRODUCTION OF COENZYME Q 10
DK1235916T3 (en) Isolated polynucleotides having a reduced content of 5'CpG3 'epigenitic control motifs and uses thereof
NZ505676A (en) Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins

Legal Events

Date Code Title Description
NUG Patent has lapsed